Endometrial Cancer clinical trials in Vermont

4 actively recruiting endometrial cancer trials at 3 sites across Vermont.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Industry

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…

Sponsor: AstraZeneca

NCT ID: NCT06989112

Sites in Vermont:

Research Site — Saint Johnsbury, Vermont

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/R…

Sponsor: Canadian Cancer Trials Group

NCT ID: NCT05640999

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont
University of Vermont and State Agricultural College — Burlington, Vermont

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company

NCT ID: NCT05768139

Sites in Vermont:

University of Vermont Medical Center — Burlington, Vermont

View on ClinicalTrials.gov →

Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska

NCT ID: NCT02012699

Sites in Vermont:

Rutland Regional Medical Center — Rutland, Vermont

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20